Divergent mechanisms for loss of Ah-responsiveness in benzo[a]pyrene- and adriamycin(R)-resistant MCF-7 cells

Biochemical Pharmacology

Volumn 57, Issue 11, 1999, Pages 1253-1263

  Caruso, Joseph A ^a   Batist, Gerald ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Adriamycin(R); Ah receptor; Arnt; Benzo a pyrene; MCF 7 cells

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; DOXORUBICIN;

ARTICLE; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BENZO(A)PYRENE; CARCINOGENS; CELL SURVIVAL; DNA, NEOPLASM; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; TETRACHLORODIBENZODIOXIN; TUMOR CELLS, CULTURED;

EID: 0033152296     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00041-6     Document Type: Article

References (62)

1. Okey A.B., Riddick D.S., Harper P.A. Molecular biology of the aromatic hydrocarbon (dioxin) receptor. Trends Pharmacol Sci. 15:1994;226-232.
2. Safe S., Krishnan V. Cellular and molecular biology of aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch Toxicol. 17:1995;99-115.
3. Ma Q., Whitlock J.P.J. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem. 272:1997;8878-8884.
4. Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J Biol Chem. 272:1997;11452-11456.
5. Bock K.W. Aryl hydrocarbon or dioxin receptor Biologic and toxic responses . Rev Physiol Biochem Pharmacol. 125:1994;1-42.
6. Obana H., Hori S., Kashmoto L., Kunita N. Polycyclic aromatic hydrocarbons in human fat and liver. Bull Environ Contam Toxicol. 27:1981;23-27.
7. Morris J.J., Seifter E. The role of aromatic hydrocarbons in the genesis of breast cancer. Med Hypotheses. 38:1992;177-184.
8. Huang Z., Fasco M.J., Figge H.L., Keyomarsi K., Kaminsky L.S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 24:1996;899-905.
9. Murray G.I., Weaver R.J., Paterson P.J., Ewen S.W.B., Melvin W.T., Burke M.D. Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol. 169:1993;347-353.
10. Albin N., Massaad L., Toussaint C., Mathieu M.C., Morizet J., Parise O., Gouyette A., Chabot G.G. Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res. 53:1993;3541-3546.
11. Stampfer M.R., Bartholomew J.C., Smith H.S., Bartley J.C. Metabolism of benzo[a]pyrene by human mammary epithelial cells Toxicity and DNA adduct formation . Proc Natl Acad Sci USA. 78:1981;6251-6255.
12. Batist G., Tulpule A., Sinha B.K., Katki A.G., Myers C.E., Cowan K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 261:1986;15544-15549.
13. Cowan K.H., Batist G., Tulpule A., Sinha B.K., Myers C.E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA. 83:1986;9328-9332.
14. Batist G., Torres G.S., Demuys J.M., Greene D., Lehnert S., Rochon M., Panasci L. Enhanced DNA cross-link removal The apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line . Mol Pharmacol. 36:1989;224-230.
15. Lehnert S., Greene D., Batist G. Radiation response of drug-resistant variants of a human breast cancer cell line. Radiat Res. 118:1989;568-580.
16. Schecter R.L., Woo A., Duong M., Batist G. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res. 51:1991;1434-1442.
17. Woo A., Tsao M.S., Batist G. Drug resistance in cultured rat liver epithelial cells spontaneously and chemically transformed. Carcinogenesis. 13:1992;1675-1677.
18. Alaoui-Jamali M.A., Batist G., Lehnert S. Radiation-induced damage to DNA in drug- and radiation-resistant sublines of a human breast cancer cell line. Radiat Res. 129:1992;37-42.
19. Fairchild C.R., Ivy S.P., Rushmore T., Lee G., Koo P., Goldsmith M.E., Myers C.E., Farber E., Cowan K.H. Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA. 84:1987;7701-7705.
20. R-resistant human breast cancer cells. Cancer Res. 47:1987;5141-5148.
21. Vickers P.J., Dufresne M.J., Cowan K.H. Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endocrinol. 3:1989;157-164.
22. Harper P.A., Prokipcak R.D., Bush L.E., Golas C.L., Okey A.B. Detection and characterization of the Ah receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the human colon adenocarcinoma cell line LS180. Arch Biochem Biophys. 290:1991;27-36.
23. Bacsi S.G., Hankinson O. Functional characterization of DNA-binding domains of the subunits of the heterodimeric aryl hydrocarbon receptor complex imputing novel and canonical basic helix-loop-helix protein-DNA interactions. J Biol Chem. 271:1996;8843-8850.
24. Coumailleau P., Poellinger L., Gustafsson J.A., Whitelaw M.L. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J Biol Chem. 270:1995;25291-25300.
25. Hayashi S., Watanabe J., Nakachi K., Eguchi H., Gotoh O., Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis. 15:1994;801-806.
26. Dolwick K.M., Schmidt J.V., Carver L.A., Swanson H.I., Bradfield C.A. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol. 44:1993;911-917.
27. Whitlock J.P.J., Galeazzi D.R. 2,3,7,8-Tetrachlorodibenzo-p-dioxin receptors in wild type and variant mouse hepatoma cells. Nuclear location and strength of nuclear binding. J Biol Chem. 259:1984;980-985.
28. Wang W.L., Thomsen J.S., Porter W., Moore M., Safe S. Effect of transient expression of the oestrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells. Br J Cancer. 73:1996;316-322.
29. Schilsky R.L., Bailey B.D., Chabner B.A. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 30:1981;1537-1542.
30. Haslam S.Z., Shyamala G. Relative distribution of estrogen and progesterone receptors among epithelial, adipose, and connective tissue components of the normal mammary gland. Endocrinology. 108:1981;825-830.
31. Whitelaw M.L., Gottlicher M., Gustafsson J.A., Poellinger L. Definition of a novel ligand binding domain of a nuclear bHLH receptor Co-localization of ligand and hsp90 binding activities within the regulable inactivation domain of the dioxin receptor . EMBO J. 12:1993;4169-4179.
32. Lindebro M.C., Poellinger L., Whitelaw M.L. Protein-protein interaction via PAS domains Role of the PAS domain in positive and negative regulation of the bHLH/PAS dioxin receptor-Arnt transcription factor complex . EMBO J. 14:1995;3528-3539.
33. Fukunaga B.N., Probst M.R., Reisz-Porszasz S., Hankinson O. Identification of the functional domains of the aryl hydrocarbon receptor. J Biol Chem. 270:1995;29270-29278.
34. Swanson H.I., Yang J.H. Mapping the protein/DNA contact sites of the Ah receptor and Ah receptor nuclear translocator. J Biol Chem. 271:1996;31657-31665.
35. Ivy S.P., Tulpule A., Fairchild C.R., Averbuch S.D., Myers C.E., Nebert D.W., Baird W.M., Cowan K.H. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem. 263:1988;19119-19125.
36. Moore M., Wang X., Lu Y.F., Wormke M., Craig A., Gerlach J.H., Burghardt R., Barhoumi R., Safe S. Benzo[a]pyrene-resistant MCF-7 human breast cancer cells. A unique aryl hydrocarbon-nonresponsive clone. J Biol Chem. 269:1994;11751-11759.
37. Moore M., Ruh M., Steinberg M., Safe S. Isolation and characterization of variant benzo[a]pyrene-resistant T47D human breast cancer cells. Int J Cancer. 66:1996;117-123.
38. Gallo M.A., Hesse E.J., Macdonald G.J., Umbreit T.H. Interactive effects of estradiol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic cytochrome P-450 and mouse uterus. Toxicol Lett. 32:1986;123-132.
39. Safe S., Astroff B., Harris M., Zacharewski T., Dickerson R., Romkes M., Biegel L. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens Characterization and mechanism of action . Pharmacol Toxicol. 69:1991;400-409.
40. Gierthy J.F., Bennett J.A., Bradley L.M., Cutler D.S. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 53:1993;3149-3153.
41. Zacharewski T.R., Bondy K.L., McDonell P., Wu Z.F. Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced pS2 expression. Cancer Res. 54:1994;2707-2713.
42. Harper N., Wang X., Liu H., Safe S. Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol Cell Endocrinol. 104:1994;47-55.
43. Thomsen J.S., Wang X., Hines R.N., Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis. 15:1994;933-937.
44. DeVito M.J., Thomas T., Martin E., Umbreit T.H., Gallo M.A. Antiestrogenic action of 2,3,7,8-tetrachlorodibenzo-p-dioxin Tissue-specific regulation of estrogen receptor in CD1 mice . Toxicol Appl Pharmacol. 113:1992;284-292.
45. Romkes M., Safe S. Comparative activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and progesterone as antiestrogens in the female rat uterus. Toxicol Appl Pharmacol. 92:1988;368-380.
46. Romkes M., Piskorska-Pliszczynska J., Safe S. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats. Toxicol Appl Pharmacol. 87:1987;306-314.
47. Berghard A., Gradin K., Pongratz I., Whitelaw M., Poellinger L. Cross-coupling of signal transduction pathways The dioxin receptor mediates induction of cytochrome P-450IA1 expression via a protein kinase C-dependent mechanism . Mol Cell Biol. 13:1993;677-689.
48. Gradin K., Whitelaw M.L., Toftgard R., Poellinger L., Berghard A. A tyrosine kinase-dependent pathway regulates ligand-dependent activation of the dioxin receptor in human keratinocytes. J Biol Chem. 269:1994;23800-23807.
49. Mahon M.J., Gasiewicz T.A. Ah receptor phosphorylation Localization of phosphorylation sites to the C-terminal half of the protein . Arch Biochem Biophys. 318:1995;166-174.
50. Wang X., Thomsen J.S., Santostefano M., Rosengren R., Safe S., Perdew G.H. Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines. Eur J Pharmacol. 293:1995;191-205.
51. Dohr O., Vogel C., Abel J. Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells. Arch Biochem Biophys. 321:1995;405-412.
52. Swanson H.I., Perdew G.H. Half-life of aryl hydrocarbon receptor in Hepa 1 cells Evidence for ligand-dependent alterations in cytosolic receptor levels . Arch Biochem Biophys. 302:1993;167-174.
53. Reick M., Robertson R.W., Pasco D.S., Fagan J.B. Down-regulation of nuclear aryl hydrocarbon receptor DNA-binding and transactivation functions Requirement for a labile or inducible factor . Mol Cell Biol. 14:1994;5653-5660.
54. Pollenz R.S., Sattler C.A., Poland A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Mol Pharmacol. 45:1994;428-438.
55. Giannone G.V., Wei L., Probst M., Okey A.B. Prolonged depletion of AH receptor without alteration of receptor mRNA levels after treatment of cells in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol. 55:1998;489-498.
56. Prokipcak R.D., Okey A.B. Downregulation of the Ah receptor in mouse hepatoma cells treated in culture with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Can J Physiol Pharmacol. 69:1991;1204-1210.
57. Yeh G.C., Lopaczynska J., Poore C.M., Phang J.M. A new functional role for P-glycoprotein Efflux pump for benzo[a]pyrene in human breast cancer MCF-7 cells . Cancer Res. 52:1992;6692-6695.
58. Pratt W.B. The role of the HSP90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol. 37:1997;297-326.
59. Chen H.S., Singh S.S., Perdew G.H. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover. Arch Biochem Biophys. 348:1997;190-198.
60. Segnitz B., Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem. 272:1997;18694-18701.
61. Wilhelmsson A., Cuthill S., Denis M., Wikstrom A.C., Gustafsson J.A., Poellinger L. The specific DNA binding activity of the dioxin receptor is modulated by the 90 kd heat shock protein. EMBO. 9:1990;69-76.
62. Sabbah M., Radanyi C., Redeuilh G., Baulieu E.E. The 90 kDa heat-shock protein (hsp90) modulates the binding of the oestrogen receptor to its cognate DNA. Biochem J. 314:1996;205-213.